$60.57
0.13% yesterday
Nasdaq, Apr 28, 10:00 pm CET
ISIN
US40637H1095
Symbol
HALO

Halozyme Therapeutics, Inc. Stock price

$60.57
-3.27 5.12% 1M
+10.11 20.04% 6M
+12.76 26.69% YTD
+21.80 56.23% 1Y
+19.07 45.95% 3Y
+37.33 160.63% 5Y
+44.77 283.35% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+0.08 0.13%
ISIN
US40637H1095
Symbol
HALO
Sector
Industry

Key metrics

Market capitalization $7.48b
Enterprise Value $8.42b
P/E (TTM) P/E ratio 17.64
EV/FCF (TTM) EV/FCF 17.98
EV/Sales (TTM) EV/Sales 8.30
P/S ratio (TTM) P/S ratio 7.37
P/B ratio (TTM) P/B ratio 20.50
Revenue growth (TTM) Revenue growth 22.44%
Revenue (TTM) Revenue $1.02b
EBIT (operating result TTM) EBIT $551.48m
Free Cash Flow (TTM) Free Cash Flow $468.37m
Cash position $596.07m
EPS (TTM) EPS $3.43
P/E forward 13.40
P/S forward 6.26
EV/Sales forward 7.05
Short interest 10.65%
Show more

Is Halozyme Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Halozyme Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

5x Buy
56%
4x Hold
44%

Analyst Opinions

9 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

Buy
56%
Hold
44%

Financial data from Halozyme Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,015 1,015
22% 22%
100%
- Direct Costs 230 230
13% 13%
23%
785 785
39% 39%
77%
- Selling and Administrative Expenses 73 73
13% 13%
7%
- Research and Development Expense 79 79
4% 4%
8%
633 633
50% 50%
62%
- Depreciation and Amortization 81 81
4% 4%
8%
EBIT (Operating Income) EBIT 551 551
63% 63%
54%
Net Profit 444 444
58% 58%
44%

In millions USD.

Don't miss a Thing! We will send you all news about Halozyme Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Halozyme Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about 22 hours ago
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m.
Neutral
PRNewsWire
about 23 hours ago
European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (...
Neutral
PRNewsWire
5 days ago
Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO , April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a...
More Halozyme Therapeutics, Inc. News

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Helen Torley
Employees 350
Founded 1998
Website www.halozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today